GynOsitol
Natural health product licensed in Canada
- Licence holder
- Pace Pharmaceuticals (Canada) Inc.
- NPN or DIN-HM
- 80078098
- Status
- Active licence
- Licence date
- 5 June 2017
- Revision date
- Not provided
- Form
- Poudre
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Myo-inositol Source : Zea mays (Whole) | 2,000 milligramme | Not calculated |
| Folate Source : Acide folique | 200 microgrammes | Not calculated |
| Folate Source : Acide folique | 15 % | Not calculated |
Non-medicinal ingredients
Maltodextrine, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 13 years | 1 packet | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
GynOsitol is a dietary supplement specific for women with PCOS that helps restore menstrual cyclicity, and helps reduce acne vulgaris and hirsutism. GynOsitol promotes ovulatory function and improves oocyte quality and helps the management of hypofertility and anovulation in women with PCOS. GynOsitol contains folic acid which is a recommended supplement for pregnant women.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
The number of patients who experienced treatment-related adverse events was low. The most frequently reported treatment-related adverse events were mild transient gastrointestinal symptoms including flatulence, loose stool and diarrhea. Nausea, diziness, insomnia, tiredness and headache were also reported at higher doses.
- Contre-indications
GynOsitol is contraindicated in patients who have a history of hypersensitivity to one of its component.
- Précautions et mises en garde
Do not exceed suggested stated recommended daily dose. GynOsitol should be stored out of the sight and reach of young children. Consult a health care professional before starting or continuing GynOsitol if you are pregnant or breastfeeding, or if you have or suspect a vitamin B12 deficiency.
Source
Official Health Canada record, licence 80078098
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.